<ul data-eligibleForWebStory="false"><li>US President Donald Trump has threatened to impose 200% tariffs on pharmaceutical products, which could significantly impact Indian drugmakers reliant on US exports.</li><li>Companies like Dr. Reddy's Laboratories, Lupin, and others will be closely monitored as a result of the tariff threat.</li><li>The Indian pharmaceutical sector faces vulnerability due to high exposure to US markets, with companies like Gland Pharma and Aurobindo Pharma having revenue exposure of around 50%.</li><li>If the tariffs are imposed, it could have a considerable impact on US consumers as India supplies approximately 40% of all generic drugs used in the country.</li></ul>

Trump Tariffs: Dr Reddy's To Lupin — Pharma Stocks To Be In Focus After Threat Of 200% Levies

Discover more